Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last 25.50 NOK
Change Today +1.10 / 4.51%
Volume 91.0K
NANO On Other Exchanges
As of 10:25 AM 07/2/15 All times are local (Market data is delayed by at least 15 minutes).

nordic nanovector asa (NANO) Snapshot

24.20 NOK
Previous Close
24.40 NOK
Day High
25.70 NOK
Day Low
23.60 NOK
52 Week High
01/28/15 - 39.00 NOK
52 Week Low
07/2/15 - 23.60 NOK
Market Cap
Average Volume 10 Days
-3.97 NOK
Shares Outstanding
Dividend Yield
Current Stock Chart for NORDIC NANOVECTOR ASA (NANO)

Related News

No related news articles were found.

nordic nanovector asa (NANO) Related Businessweek News

No Related Businessweek News Found

nordic nanovector asa (NANO) Details

Nordic Nanovector ASA, a biotech company, develops, manufactures, and delivers antibody-radionuclide-conjugate (ARC) clinical solutions to address unmet medical needs and advance cancer care in patients. Its lead product candidate is Betalutin, an ARC that is in Phase I/II clinical trial for the treatment of patients with non-hodgkin lymphoma, a life-threatening blood cancer. The company was formerly known as Nordic Nanovector AS and changed its name to Nordic Nanovector ASA in 2014. Nordic Nanovector ASA was founded in 2009 and is headquartered in Oslo, Norway.

24 Employees
Last Reported Date: 05/27/15
Founded in 2009

nordic nanovector asa (NANO) Top Compensated Officers

Chief Executive Officer
Total Annual Compensation: 907.3K NOK
Chief Financial Officer
Total Annual Compensation: 1.1M NOK
Chief Operations Officer
Total Annual Compensation: 1.3M NOK
Chief Quality Officer
Total Annual Compensation: 868.1K NOK
Chief Clinical Officer
Total Annual Compensation: 741.2K NOK
Compensation as of Fiscal Year 2014.

nordic nanovector asa (NANO) Key Developments

Nordic Nanovector Announces Updated Results of its Ongoing Phase 1/2 Study with Betalutin

Nordic Nanovector ASA announced updated results of its ongoing Phase 1/2 study with Betalutin in relapsed CD37+ non-Hodgkin lymphoma patients. This Phase 1/2 single dose, open label, dose-finding study is investigating three dose levels of Betalutin in 13 patients with relapsed CD37+ NHL, previously treated with a number of regimens ranging from 1 to 8. The updated data confirm the favorable safety profile of Betalutin and its promising efficacy. New data also highlight that clinical responses observed are sustained, with 5 out of 7 patients still in response, and a duration of response ranging from 6 to 21+ months.

Nordic Nanovector ASA Reports Un-Audited Consolidated Earnings Results for the First Quarter Ended March 31, 2015

Nordic Nanovector ASA reported un-audited consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported revenues of NOK 76,041 compared to NOK 118,143, operating loss of NOK 35.8 million compared to NOK 11.9 million, loss before income tax of NOK 33.7 million compared to NOK 11.3 million, loss for the period attributable to owners of the company of NOK 33.7 million or NOK 1.18 per basic and diluted share compared to NOK 11.3 million or NOK 1.02 per basic and diluted share, net cash out flow from operating activities of NOK 26.7 million compared to NOK 12.0 million and investments in property plant and equipment and intangible assets of NOK 1.4 million compared to NOK 0.4 million for the last year.

Nordic Nanovector ASA Announces Revenue Results for the First Quarter of 2015

Nordic Nanovector ASA announced revenue results for the first quarter of 2015. For the quarter, the company reported revenues amounted to NOK 76,041 compared to NOK 118,143 a year ago.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NANO:NO 25.50 NOK +1.10

NANO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for NANO.
View Industry Companies

Industry Analysis


Industry Average

Valuation NANO Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 2,651.3x
Price/Book 2.0x
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NORDIC NANOVECTOR ASA, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at